Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
60 participants
INTERVENTIONAL
2023-02-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cannabinoid Supplementation on Vascular and Cognitive Function
NCT03295903
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
NCT06859710
Modulation of THC Effects by CBD: a Dose-ranging Study
NCT06099379
The Pharmacodynamics of Cannabinoid-Caffeine Combinations
NCT05478863
Acute Effects of Cannabis on Cognition and Affect
NCT07296874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo (CBD 0%)
Participants are required to vaporize a placebo at 0% CBD concentration
Placebo (CBD 0%)
Participants are required to vaporize placebo at 0% CBD concentration
CBD 15%
Participants are required to vaporize CBD at a concentration of 15%.
CBD 15%
Participants are required to vaporize CBD at a concentration of 15%.
CBD 30%
Participants are required to vaporize CBD at a concentration of 30%.
CBD 30%
Participants are required to vaporize CBD at a concentration of 30%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo (CBD 0%)
Participants are required to vaporize placebo at 0% CBD concentration
CBD 15%
Participants are required to vaporize CBD at a concentration of 15%.
CBD 30%
Participants are required to vaporize CBD at a concentration of 30%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a current driving licence
* Have at least one year's driving experience
* Drive at least once a week
* Monocular visual acuity of at least 6/6 (Snellen) with habitual correction for driving
* Absence of binocular disorders
Exclusion Criteria
* Current cannabis or alcohol use disorder
* Use of other drugs
* Pregnancy or lactation
* Simulator sickness.
18 Years
43 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de Granada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sonia Ortiz Peregrina
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Granada
Granada, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-EXP-194-UGR23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.